Welcome to the SCW blog, where we share practical insights on building faster, more resilient, and more compliant supply chains in life sciences and other regulated industries. Here, we translate real transformation work into clear takeaways, from strategy to execution, so teams can move from “where do we start?” to measurable impact.
The pharma supply chain is not a forgiving environment for shortcuts. The processes are complex, the regulatory exposure is real, and the downstream impact of poor data or unclear ownership is significant. Autonomous actions, at any meaningful scale, require you to have already solved for that complexity, not planned to solve it later.
Reducing alerts is often framed as an execution problem, how quickly can teams investigate and close them? But in practice, the real issue is different. It is not the volume of alerts, but the quality of those alerts.
The critical detail most teams miss is that AMS access is OBP-based, not MAH-based and as defined by EMVO, OBPs can create users and structure them into teams to control alert visibility by market. The practical implication is that onboarding success depends on how entities, teams, market coverage, and ownership are designed, not simply on system access.
The European Medicines Verification System (EMVS) only works at scale when alerts are handled quickly, consistently, and with high-quality data. A single alert at dispensing can trigger quarantine procedures, investigations, and communication with national verification organizations. When this happens across hundreds of SKUs, multiple CMOs, and many European markets, the operational workload grows rapidly.
This article focuses on DSCSA from an operational execution perspective, how interoperability behaves inside daily warehouse, quality, and supply chain workflows.
This white paper blends the original high-level summary with a more detailed narrative, offering both clear structure and practical depth. It explains the new NDC format, explores stakeholder impacts, describes the implications for GTIN, and outlines concrete next steps and emerging solution options.
This blog post will explore the power of hyperautomation, its most impactful applications, and the strategic guidance needed to navigate the inevitable workforce and cultural shifts, highlighting quick wins that many competitors overlook.
For decades, the global pharmaceutical industry operated on a model of maximum efficiency, often driven by the pursuit of the lowest cost. This led to a highly complex, geographically dispersed pharma supply chain, with raw material suppliers, API (Active Pharmaceutical Ingredient) manufacturers, and drug packagers often located thousands of miles from the end consumer.
Personalized medicine, or precision medicine, is a fundamental change in how we treat disease. Instead of a single drug for a broad population, these therapies are designed for a patient’s unique biological and genetic profile.
